Technology area: Biotechnology & Pharmaceuticals
38 pending office actions • 17 art units • 32 examiners • 0 of 38 (0%) have an AI response strategy ready • 35 patents granted in the last 365 days
Gilead Sciences Inc. has 38 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 32 distinct examiners and 17 distinct art units, indicating recurring assignments within a relatively focused set of technical units. Unit-level monitoring may help identify patterns in biotechnology examination, while examiner-specific preparation remains necessary.
LEE, ANDREW P is the busiest examiner, with 3 pending matters. That concentration supports coordinated review of those matters for common claim and prior-art issues, but it does not define the full docket. Counsel should maintain consistent scientific terminology and disclosure positions across applications without assuming uniform treatment.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (5%) |
| §103 only | 6 (16%) |
| §102 only | 4 (11%) |
| §112 only | 10 (26%) |
| Double-patenting only | 2 (5%) |
| Double-patenting + other | 5 (13%) |
| Multi-statute (no §101) | 9 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, ANDREW P | 3 | 48.5% | +22.8% |
| KIFLE, BRUCK | 2 | 79.3% | +15.8% |
| SEUDIEU SEUDIEU, CARINE PATRICIA | 2 | — | — |
| MARTIN, KEVIN STEPHEN | 2 | 77.4% | +23.3% |
| LEWIS, PATRICK T | 2 | 74.0% | +14.5% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| PIHONAK, SARAH | 1 | 61.4% | +42.4% |
| STANLEY, JARROD LEE | 1 | — | — |
| HALL, DEANNA K | 1 | 75.7% | +15.3% |
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18829547 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | HAMA, JOANNE | 2d overdue |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | GRIZER, CASSANDRA SENN | 8d |
| 18900367 | Medical Injections | HALL, DEANNA K | — |
| 18819051 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LEWIS, PATRICK T | — |
| 18816988 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LEWIS, PATRICK T | — |
| 18785641 | WEEKLY REGIMEN FOR HIV | SAMSELL, RILLA MARIE | — |
| 18754347 | METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS | FADHEL, ALI Z | — |
| 18754794 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | SAWYER, JENNIFER C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18313266 | DARUNAVIR COMBINATION FORMULATIONS | LEE, ANDREW P | 26d overdue |
| 19255499 | TREATMENT OF HR+/HER2- BREAST CANCER USING SACITUZUMAB GOVITECAN | PUTTLITZ, KARL J | — |
| 19045761 | SARS-COV2 MAIN PROTEASE INHIBITORS | PIHONAK, SARAH | — |
| 18938633 | MCL1 INHIBITORS | KIFLE, BRUCK | — |
| 18918629 | MCL-1 INHIBITORS | KIFLE, BRUCK | — |
| 18900367 | Medical Injections | HALL, DEANNA K | — |
| 18899540 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | MARTIN, KEVIN STEPHEN | — |
| 18819051 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LEWIS, PATRICK T | — |
| Art Unit | Apps |
|---|---|
| 1691 | 7 |
| 1624 | 5 |
| 1626 | 5 |
| 1627 | 3 |
| 1672 | 3 |
| 1628 | 2 |
| 1647 | 2 |
| 1646 | 1 |
| 3783 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19255499 | TREATMENT OF HR+/HER2- BREAST CANCER USING SACITUZUMAB GOVITECAN | PUTTLITZ, KARL J | 1646 | §103§112DP | Final Rejection | — | Pending | Jun 30, 2025 |
| 19045761 | SARS-COV2 MAIN PROTEASE INHIBITORS | PIHONAK, SARAH | 1627 | §112 | Non-Final OA | — | Pending | Feb 05, 2025 |
| 18938633 | MCL1 INHIBITORS | KIFLE, BRUCK | 1624 | §112Other | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18918629 | MCL-1 INHIBITORS | KIFLE, BRUCK | 1624 | §112Other | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18911325 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | STANLEY, JARROD LEE | — | §102Other | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18911340 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SEUDIEU SEUDIEU, CARINE PATRICIA | 1626 | §102Other | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18911404 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SEUDIEU SEUDIEU, CARINE PATRICIA | 1626 | §102Other | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18900367 | Medical Injections | HALL, DEANNA K | 3783 | §102§103 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18899540 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | MARTIN, KEVIN STEPHEN | 1624 | §112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18829547 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | AULAKH, CHARANJIT | 1621 | §112DP | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18827510 | KRAS G12D MODULATING COMPOUNDS | SHIAO, REI TSANG | 1691 | §102§103DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18819051 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LEWIS, PATRICK T | 1691 | §101§112Other | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18818487 | SOLID FORMS OF FXR AGONISTS | MARTIN, KEVIN STEPHEN | 1624 | §112Other | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18816988 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LEWIS, PATRICK T | 1691 | §101§112Other | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18812842 | DOSING REGIMEN OF HIV CAPSID INHIBITOR | HASTINGS, ALISON AZAR | 1627 | §102§103DP | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18804677 | PHARMACEUTICAL FORMULATIONS OF BICTEGRAVIR AND LENACAPAVIR | KASSA, TIGABU | 1619 | §103 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18785641 | WEEKLY REGIMEN FOR HIV | SAMSELL, RILLA MARIE | 1624 | §102§103§112Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18758879 | PROCESSES FOR MAKING IRAK4 INHIBITORS | FETTEROLF, BRANDON J | 1626 | §102 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18754347 | METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS | FADHEL, ALI Z | 1772 | §102§103 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18754794 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | SAWYER, JENNIFER C | 1691 | §102§103§112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18747316 | FXR (NR1H4) MODULATING COMPOUNDS | HOWELL, THEODORE R | 1628 | DP | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18743701 | HIV VACCINES AND METHODS OF USING | KINSEY WHITE, NICOLE ERIN | 1672 | §112Other | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18731608 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | LEE, ANDREW P | 1691 | DP | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18678444 | THERAPEUTIC COMPOUNDS FOR HIV | WHITE, DAWANNA SHAR-DAY | 1627 | §103 | Non-Final OA | — | Pending | May 30, 2024 |
| 18678355 | SOLID FORMS | CORNET, JEAN P | 1628 | §103§112Other | Non-Final OA | — | Pending | May 30, 2024 |
| 18645671 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | KRISHNAN, GANAPATHY | 1693 | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18540652 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18499540 | ANTICANCER THERAPIES USING ANTI-CCR8 ANTIBODY, CHEMO AND IMMUNOTHERAPY COMBINATIONS | BERHANE, SELAM | 1675 | §112 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18495712 | METHODS OF TREATING LIVER DISEASE | SIMMONS, CHRIS E | 1622 | §103 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Final Rejection | 8d | Pending | Aug 11, 2023 |
| 18344560 | CD73 COMPOUNDS | SEITZ, ANTHONY JOSEPH | 1629 | §112 | Non-Final OA | 69d | Pending | Jun 29, 2023 |
| 18205745 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | MAHLUM, JONATHAN DAVIS | 1625 | §103§112DP | Non-Final OA | — | Pending | Jun 05, 2023 |
| 18314989 | SOLID FORMS OF A COMPOUND FOR MODULATING COT | LEE, ANDREW P | 1691 | §112 | Non-Final OA | — | Pending | May 10, 2023 |
| 18313266 | DARUNAVIR COMBINATION FORMULATIONS | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 26d overdue | Pending | May 05, 2023 |
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | HAMA, JOANNE | 1647 | §103§112Other | Non-Final OA | 2d overdue | Pending | Apr 03, 2023 |
| 17636511 | PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE | JACKSON, SHAWQUIA | 1626 | §103 | Non-Final OA | 77d | Pending | Feb 18, 2022 |
| 17612426 | DOSAGE REGIMENS FOR VACCINES | JADHAO, SAMADHAN JAISING | 1672 | §103Other | Final Rejection | 31d overdue | Pending | Nov 18, 2021 |
| 16882804 | THERAPEUTIC COMPOUNDS | COUGHLIN, MATTHEW P | 1626 | §102§112 | Non-Final OA | — | Pending | May 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGilead Sciences Inc. has 38 pending office actions as of October 2026, spread across 17 art units and 32 examiners.
Andrew P Lee has the most, with 3 of Gilead Sciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
